Sanofi Total Current Assets 2012-2026 | SNY
Sanofi total current assets from 2012 to 2026. Total current assets can be defined as the sum of all assets that are classified as current because they will provide a benefit within one year.
- Sanofi total current assets for the quarter ending March 31, 2026 were $35.304B, a 23.87% decline year-over-year.
- Sanofi total current assets for 2024 were $46.084B, a 38.83% increase from 2023.
- Sanofi total current assets for 2023 were $33.194B, a 7.41% decline from 2022.
- Sanofi total current assets for 2022 were $35.85B, a 0.86% decline from 2021.
|
Sanofi Annual Total Current Assets (Millions of US $) |
|
|---|---|
| 2024 | $46,084 |
| 2023 | $33,194 |
| 2022 | $35,850 |
| 2021 | $36,160 |
| 2020 | $38,499 |
| 2019 | $32,044 |
| 2018 | $29,028 |
| 2017 | $29,786 |
| 2016 | $29,532 |
| 2015 | $27,680 |
| 2014 | $31,142 |
| 2013 | $31,762 |
| 2012 | $29,323 |
| 2011 | $29,051 |
|
Sanofi Quarterly Total Current Assets (Millions of US $) |
|
|---|---|
| 2026-03-31 | $35,304 |
| 2025-12-31 | $35,019 |
| 2025-09-30 | $39,792 |
| 2025-06-30 | $42,022 |
| 2025-03-31 | $46,374 |
| 2024-12-31 | $46,084 |
| 2024-09-30 | |
| 2024-06-30 | $32,392 |
| 2024-03-31 | |
| 2023-12-31 | $33,194 |
| 2023-09-30 | |
| 2023-06-30 | $32,686 |
| 2023-03-31 | |
| 2022-12-31 | $35,850 |
| 2022-09-30 | |
| 2022-06-30 | $30,181 |
| 2022-03-31 | |
| 2021-09-30 | |
| 2021-03-31 | |
| 2020-09-30 | |
| 2020-03-31 | |
| 2019-09-30 | |
| 2019-03-31 | |
| 2018-03-31 | |
| 2017-12-31 | $29,786 |
| 2017-09-30 | |
| 2017-06-30 | $29,784 |
| 2017-03-31 | |
| 2016-12-31 | $29,532 |
| 2016-09-30 | |
| 2016-06-30 | $25,230 |
| 2016-03-31 | |
| 2015-09-30 | |
| 2015-06-30 | $24,346 |
| 2014-06-30 | $27,942 |
| 2013-06-30 | $27,172 |
| 2012-06-30 | $27,563 |
| 2012-03-31 | |
| 2011-12-31 | $29,051 |
| 2011-09-30 | |
| 2011-06-30 | $32,571 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $114.048B | $49.347B |
| Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |